Ez-OX

Ez-Ox is a French biotechnology company specializing in the development of next-generation hemoglobin-based oxygen carriers (HBOCs). Founded as a spin-off from the University of Bordeaux and the CNRS, the company aims to solve the historical challenges of synthetic blood substitutes, such as vasoconstriction and oxidative stress. Its proprietary technology focuses on a highly stable, non-toxic hemoglobin molecule designed for efficient oxygen transport and release. The company's primary clinical targets include organ preservation for transplantation and the treatment of hemorrhagic shock in emergency settings. Ez-Ox is currently in the pre-clinical stage, advancing its lead candidates toward human trials to provide a reliable alternative to traditional blood transfusions.